Abstract
Purpose
To investigate the steady-state pharmacokinetics of moxifloxacin in critically ill patients after intravenous administration of the 400 mg fixed dose.
Methods
Fifteen adult patients with severe sepsis (n = 3) or septic shock (n = 12) were enrolled in this dual-centre, prospective, open-label study. Moxifloxacin was administered with the recommended dose of 400 mg once daily i.v. for at least 5 days. Blood samples were obtained before and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 and 24 h after the third administration. Moxifloxacin concentrations in plasma were measured by HPLC with fluorescence detection.
Results
Data for 400 mg moxifloxacin i.v. were as follows (geometric mean): C max: 3.5 mg/l, t ½: 7.8 h and AUC (48–72 h): 25 mg h/l. In five individual patients AUC (48–72 h) was <20 mg h/l.
Conclusion
The main pharmacokinetics/pharmacodynamics parameter predicting clinical efficacy of moxifloxacin is AUC/MIC. The mean AUC of patients with severe sepsis or septic shock was lower compared to healthy volunteers (39 mg h/l). In 5 of 12 patients the AUC was halved compared to healthy volunteers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009–1034
Power BM, Forbes AM, van Heerden PV, Ilett KF (1998) Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 34:25–56
Bion J, Jaeschke R, Thompson BT, Levy M, Dellinger RP (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:1163–1164
Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 43(Suppl B):83–90
Schentag JJ, Meagher AK, Forrest A (2003) Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 37:1478–1488
Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH (2008) Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig 28:71–79
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470
Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–1060
Acknowledgments
This study was supported the German Competence Network Sepsis (SepNet) funded by the Federal Ministry of Education and Research (BMBF, Grant no. 01 KI 0106) and by an unrestricted grant from Bayer Healthcare, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pletz, M.W., Bloos, F., Burkhardt, O. et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med 36, 979–983 (2010). https://doi.org/10.1007/s00134-010-1864-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-010-1864-y